Skip to main content
Erschienen in: Current HIV/AIDS Reports 1/2015

01.03.2015 | The Science of Prevention (JD Stekler, Section Editor)

Novel Interventions to Prevent HIV and HCV Among Persons Who Inject Drugs

verfasst von: Phillip O. Coffin, Christopher Rowe, Glenn-Milo Santos

Erschienen in: Current HIV/AIDS Reports | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Persons who inject drugs (PWID) are at high risk for infection with and poor outcomes from HIV and hepatitis C virus (HCV). Well-established interventions for HIV/HCV prevention among PWID include syringe access, opioid agonist maintenance treatment, and supervised injection facilities, yet these interventions remain unavailable or inadequately resourced in much of the world. We review recent literature on biomedical and behavioral interventions to reduce the burden of HIV/HCV among PWID, with an emphasis on randomized controlled trials and quasi-experimental studies. Since 2013, there have been significant advancements in utilizing antiviral therapy and behavioral interventions for prevention among PWID, including approaches that address the unique needs of couples and sex workers. In addition, there have been significant developments in pharmacotherapies for substance use and the implementation of naloxone for opioid overdose prevention. Notwithstanding multiple ongoing structural challenges in delivering HIV/HCV prevention interventions to PWID, these emerging and rigorously evaluated interventions expand possibilities for prevention among PWID.
Literatur
1.
Zurück zum Zitat Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45. doi:10.1016/S0140-6736(08)61311-2.CrossRefPubMed Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45. doi:10.​1016/​S0140-6736(08)61311-2.CrossRefPubMed
2.
Zurück zum Zitat Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS response progress reporting (GARPR). Geneva, Switzerland2014. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS response progress reporting (GARPR). Geneva, Switzerland2014.
4.
Zurück zum Zitat Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1564–74. doi:10.1016/S0140-6736(13)61530-5.CrossRefPubMed Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1564–74. doi:10.​1016/​S0140-6736(13)61530-5.CrossRefPubMed
6.
Zurück zum Zitat Centers for Disease Control and Prevention. Viral Hepatitis Surveillance: United States, 2011. In: Hepatitis DoV, editor. Atlanta GA2013. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance: United States, 2011. In: Hepatitis DoV, editor. Atlanta GA2013.
7.
Zurück zum Zitat Ward J. The epidemiology of hepatitis C: how did we get here? Centers for Disease Prevention and Control Public Health Grand Rounds; 17 June; Atlanta GA 2014. Ward J. The epidemiology of hepatitis C: how did we get here? Centers for Disease Prevention and Control Public Health Grand Rounds; 17 June; Atlanta GA 2014.
9.
Zurück zum Zitat Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014–28. doi:10.1016/S0140-6736(10)60232-2.CrossRefPubMed Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014–28. doi:10.​1016/​S0140-6736(10)60232-2.CrossRefPubMed
10.
Zurück zum Zitat Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17(9):2878–92. doi:10.1007/s10461-013-0593-y.CrossRefPubMed Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17(9):2878–92. doi:10.​1007/​s10461-013-0593-y.CrossRefPubMed
11.
Zurück zum Zitat Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301. doi:10.1016/S0140-6736(10)60742-8.CrossRefPubMed Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301. doi:10.​1016/​S0140-6736(10)60742-8.CrossRefPubMed
12.
Zurück zum Zitat Joint United Nations Programme on HIV/AIDS (UNAIDS). The GAP Report. Geneva, Switzerland: UNAIDS2014 July 2014 Contract No.: ISBN 978-92-9253-062-4. Joint United Nations Programme on HIV/AIDS (UNAIDS). The GAP Report. Geneva, Switzerland: UNAIDS2014 July 2014 Contract No.: ISBN 978-92-9253-062-4.
13.
Zurück zum Zitat Chiu J, Burris S. Punitive drug law and the risk environment for injecting drug users: understanding the connections. 2011. Chiu J, Burris S. Punitive drug law and the risk environment for injecting drug users: understanding the connections. 2011.
17.••
Zurück zum Zitat Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90. This is the first study of PrEP exclusively among PWID and demonstrates efficacy of the intervention.CrossRefPubMed Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90. This is the first study of PrEP exclusively among PWID and demonstrates efficacy of the intervention.CrossRefPubMed
20.
Zurück zum Zitat World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva Switzerland2014. p. Pages xviii, 39. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva Switzerland2014. p. Pages xviii, 39.
22.
Zurück zum Zitat Kirk G, Galai N, Astemborski J, Linas B, Celentano D, Mehta S et al. Decline in community viral load strongly associated with declining HIV incidence among IDU. 18th Conference on Retrovirusses and Opportunistic Infections; February 27–March 2, 2011; Boston, MA: CROI; 2011. p. 484. Kirk G, Galai N, Astemborski J, Linas B, Celentano D, Mehta S et al. Decline in community viral load strongly associated with declining HIV incidence among IDU. 18th Conference on Retrovirusses and Opportunistic Infections; February 27–March 2, 2011; Boston, MA: CROI; 2011. p. 484.
23.
Zurück zum Zitat Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.CrossRefPubMedCentralPubMed Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2009;49(4):561–73. doi:10.1086/600304.CrossRef Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2009;49(4):561–73. doi:10.​1086/​600304.CrossRef
28.
Zurück zum Zitat Putka B, Mullen K, Birdi S, Merheb M. The disposition of hepatitis C antibody-positive patients in an urban hospital. J Viral Hepat. 2009;16(11):814–21.CrossRefPubMed Putka B, Mullen K, Birdi S, Merheb M. The disposition of hepatitis C antibody-positive patients in an urban hospital. J Viral Hepat. 2009;16(11):814–21.CrossRefPubMed
31.
Zurück zum Zitat Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136(4):288–92.CrossRefPubMed Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136(4):288–92.CrossRefPubMed
35.
Zurück zum Zitat Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23. doi:10.1016/S0140-6736(13)62121-2.CrossRefPubMed Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23. doi:10.​1016/​S0140-6736(13)62121-2.CrossRefPubMed
37.
38.
Zurück zum Zitat Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88. doi:10.1056/NEJMoa1402355.CrossRefPubMed Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88. doi:10.​1056/​NEJMoa1402355.CrossRefPubMed
39.
Zurück zum Zitat Townsend KS, Osinusi A, Nelson AK, Kohli A, Gross C, Polis MA et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on or off antiretroviral therapy: results from the NIAID ERADICATE trial. American Association for the Study of Liver Diseases: The Liver Meeting 2014; 7–11 November 2014; Boston MA 2014. Townsend KS, Osinusi A, Nelson AK, Kohli A, Gross C, Polis MA et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on or off antiretroviral therapy: results from the NIAID ERADICATE trial. American Association for the Study of Liver Diseases: The Liver Meeting 2014; 7–11 November 2014; Boston MA 2014.
40.
Zurück zum Zitat Lawitz EJ, Hebner CM, Pang PS, Hyland RH, Miller MD, Mo H et al. Sofosbuvir/ledipasvir fixed dose combination is highly effective in subjects with baseline NS5A inhibitor and NS3 protease inhibitor resistance-associated variants: the Lonestar Trial (Abstract #1844). The Liver Meeting 2013; 1–5 November 2013; Washington DC 2013. Lawitz EJ, Hebner CM, Pang PS, Hyland RH, Miller MD, Mo H et al. Sofosbuvir/ledipasvir fixed dose combination is highly effective in subjects with baseline NS5A inhibitor and NS3 protease inhibitor resistance-associated variants: the Lonestar Trial (Abstract #1844). The Liver Meeting 2013; 1–5 November 2013; Washington DC 2013.
41.•
Zurück zum Zitat Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013. doi:10.1002/hep.26431. An important exercise in estimating the potential benefit of “treatment as prevention” for HCV among PWID.PubMedCentral Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013. doi:10.​1002/​hep.​26431. An important exercise in estimating the potential benefit of “treatment as prevention” for HCV among PWID.PubMedCentral
42.
Zurück zum Zitat Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2013;57 Suppl 2:S32–8. doi:10.1093/cid/cit300.CrossRef Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2013;57 Suppl 2:S32–8. doi:10.​1093/​cid/​cit300.CrossRef
43.
Zurück zum Zitat Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2013;56(3):405–13. doi:10.1093/cid/cis921.CrossRef Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2013;56(3):405–13. doi:10.​1093/​cid/​cis921.CrossRef
44.
Zurück zum Zitat Hilsden RJ, Macphail G, Grebely J, Conway B, Lee SS. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2013;57 Suppl 2:S90–6. doi:10.1093/cid/cit327.CrossRef Hilsden RJ, Macphail G, Grebely J, Conway B, Lee SS. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2013;57 Suppl 2:S90–6. doi:10.​1093/​cid/​cit327.CrossRef
45.
Zurück zum Zitat Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645–53.CrossRefPubMed Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645–53.CrossRefPubMed
46.
Zurück zum Zitat Purcell DW, Latka MH, Metsch LR, Latkin CA, Gomez CA, Mizuno Y, et al. Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr. 2007;46 Suppl 2:S35–47. doi:10.1097/QAI.0b013e31815767c4.CrossRefPubMed Purcell DW, Latka MH, Metsch LR, Latkin CA, Gomez CA, Mizuno Y, et al. Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr. 2007;46 Suppl 2:S35–47. doi:10.​1097/​QAI.​0b013e31815767c4​.CrossRefPubMed
47.
Zurück zum Zitat Mackesy-Amiti ME, Finnegan L, Ouellet LJ, Golub ET, Hagan H, Hudson SM, et al. Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study. AIDS Behav. 2013;17(6):2075–83. doi:10.1007/s10461-012-0373-0.CrossRefPubMedCentralPubMed Mackesy-Amiti ME, Finnegan L, Ouellet LJ, Golub ET, Hagan H, Hudson SM, et al. Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study. AIDS Behav. 2013;17(6):2075–83. doi:10.​1007/​s10461-012-0373-0.CrossRefPubMedCentralPubMed
49.••
Zurück zum Zitat El-Bassel N, Gilbert L, Terlikbayeva A, Beyrer C, Wu E, Chang M, et al. Effects of a couple-based intervention to reduce risks for HIV, HCV, and STIs among drug-involved heterosexual couples in Kazakhstan: a randomized controlled trial. J Acquir Immune Defic Syndr. 2014;67(2):196–203. doi:10.1097/QAI.0000000000000277. This full-sized RCT demonstrated the efficacy of a couple-based behavioral intervention among PWID in preventing HCV incidence.CrossRefPubMed El-Bassel N, Gilbert L, Terlikbayeva A, Beyrer C, Wu E, Chang M, et al. Effects of a couple-based intervention to reduce risks for HIV, HCV, and STIs among drug-involved heterosexual couples in Kazakhstan: a randomized controlled trial. J Acquir Immune Defic Syndr. 2014;67(2):196–203. doi:10.​1097/​QAI.​0000000000000277​. This full-sized RCT demonstrated the efficacy of a couple-based behavioral intervention among PWID in preventing HCV incidence.CrossRefPubMed
50.••
Zurück zum Zitat Strathdee SA, Abramovitz D, Lozada R, Martinez G, Rangel MG, Vera A, et al. Reductions in HIV/STI incidence and sharing of injection equipment among female sex workers who inject drugs: results from a randomized controlled trial. PLoS One. 2013;8(6):e65812. doi:10.1371/journal.pone.0065812. This interactive risk behavior intervention among female sex workers who inject drugs demonstrated a significant reduction in both sexually transmitted infections and HIV incidence.CrossRefPubMedCentralPubMed Strathdee SA, Abramovitz D, Lozada R, Martinez G, Rangel MG, Vera A, et al. Reductions in HIV/STI incidence and sharing of injection equipment among female sex workers who inject drugs: results from a randomized controlled trial. PLoS One. 2013;8(6):e65812. doi:10.​1371/​journal.​pone.​0065812. This interactive risk behavior intervention among female sex workers who inject drugs demonstrated a significant reduction in both sexually transmitted infections and HIV incidence.CrossRefPubMedCentralPubMed
51.•
Zurück zum Zitat Mateu-Gelabert P, Gwadz MV, Guarino H, Sandoval M, Cleland CM, Jordan A, et al. The staying safe intervention: training people who inject drugs in strategies to avoid injection-related HCV and HIV infection. AIDS Educ Prev : Off Publ Int Soc AIDS Educ. 2014;26(2):144–57. doi:10.1521/aeap.2014.26.2.144. Although only a pilot study, this promising strength-based intervention demonstrated reductions in HCV risk behaviors.CrossRef Mateu-Gelabert P, Gwadz MV, Guarino H, Sandoval M, Cleland CM, Jordan A, et al. The staying safe intervention: training people who inject drugs in strategies to avoid injection-related HCV and HIV infection. AIDS Educ Prev : Off Publ Int Soc AIDS Educ. 2014;26(2):144–57. doi:10.​1521/​aeap.​2014.​26.​2.​144. Although only a pilot study, this promising strength-based intervention demonstrated reductions in HCV risk behaviors.CrossRef
52.
Zurück zum Zitat Mayor AM, Fernandez DM, Colon H, Thomas JC, Miranda C, Hunter-Mellado RF. Hepatitis-C multimedia prevention program in poor Hispanic HIV-infected injecting drug users: six months after intervention. J Health Care Poor Underserved. 2013;24(4 Suppl):29–37. doi:10.1353/hpu.2014.0015.PubMedCentralPubMed Mayor AM, Fernandez DM, Colon H, Thomas JC, Miranda C, Hunter-Mellado RF. Hepatitis-C multimedia prevention program in poor Hispanic HIV-infected injecting drug users: six months after intervention. J Health Care Poor Underserved. 2013;24(4 Suppl):29–37. doi:10.​1353/​hpu.​2014.​0015.PubMedCentralPubMed
54.
Zurück zum Zitat Wang K, Fu H, Longfield K, Modi S, Mundy G, Firestone R. Do community-based strategies reduce HIV risk among people who inject drugs in China? Quasi-exp Study Yunnan Guangxi Provinces Harm Reduction J. 2014;11:15. doi:10.1186/1477-7517-11-15.CrossRef Wang K, Fu H, Longfield K, Modi S, Mundy G, Firestone R. Do community-based strategies reduce HIV risk among people who inject drugs in China? Quasi-exp Study Yunnan Guangxi Provinces Harm Reduction J. 2014;11:15. doi:10.​1186/​1477-7517-11-15.CrossRef
55.
Zurück zum Zitat Latkin C, Donnell D, Liu TY, Davey-Rothwell M, Celentano D, Metzger D. The dynamic relationship between social norms and behaviors: the results of an HIV prevention network intervention for injection drug users. Addiction. 2013;108(5):934–43. doi:10.1111/add.12095.CrossRefPubMedCentralPubMed Latkin C, Donnell D, Liu TY, Davey-Rothwell M, Celentano D, Metzger D. The dynamic relationship between social norms and behaviors: the results of an HIV prevention network intervention for injection drug users. Addiction. 2013;108(5):934–43. doi:10.​1111/​add.​12095.CrossRefPubMedCentralPubMed
56.
58.
Zurück zum Zitat Dunn KE, Fingerhood M, Wong CJ, Svikis DS, Nuzzo P, Silverman K. Employment-based abstinence reinforcement following inpatient detoxification in HIV-positive opioid and/or cocaine-dependent patients. Exp Clin Psychopharmacol. 2014;22(1):75–85. doi:10.1037/a0034863.CrossRefPubMedCentralPubMed Dunn KE, Fingerhood M, Wong CJ, Svikis DS, Nuzzo P, Silverman K. Employment-based abstinence reinforcement following inpatient detoxification in HIV-positive opioid and/or cocaine-dependent patients. Exp Clin Psychopharmacol. 2014;22(1):75–85. doi:10.​1037/​a0034863.CrossRefPubMedCentralPubMed
59.
Zurück zum Zitat Holtyn AF, Koffarnus MN, Defulio A, Sigurdsson SO, Strain EC, Schwartz RP, et al. The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial. Prev Med. 2014. doi:10.1016/j.ypmed.2014.02.021.PubMed Holtyn AF, Koffarnus MN, Defulio A, Sigurdsson SO, Strain EC, Schwartz RP, et al. The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial. Prev Med. 2014. doi:10.​1016/​j.​ypmed.​2014.​02.​021.PubMed
60.•
Zurück zum Zitat Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—outcomes of a randomized trial. Drug Alcohol Depend. 2013;133(2):376–82. doi:10.1016/j.drugalcdep.2013.06.024. Although the effectiveness of agonist maintenance treatment in reducing substance use and HIV risk behaviors is well-established, replicating these findings in regions of the world that have not had access to the treatments remains an important advance.CrossRefPubMed Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—outcomes of a randomized trial. Drug Alcohol Depend. 2013;133(2):376–82. doi:10.​1016/​j.​drugalcdep.​2013.​06.​024. Although the effectiveness of agonist maintenance treatment in reducing substance use and HIV risk behaviors is well-established, replicating these findings in regions of the world that have not had access to the treatments remains an important advance.CrossRefPubMed
62.•
Zurück zum Zitat Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628–37. doi:10.1111/add.12208. Should long-acting naltrexone prove viable in other settings, this represents a significant expansion in the options for persons with opioid use disorders.CrossRefPubMed Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628–37. doi:10.​1111/​add.​12208. Should long-acting naltrexone prove viable in other settings, this represents a significant expansion in the options for persons with opioid use disorders.CrossRefPubMed
63.
Zurück zum Zitat Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–13. doi:10.1016/S0140-6736(11)60358-9.CrossRefPubMed Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–13. doi:10.​1016/​S0140-6736(11)60358-9.CrossRefPubMed
64.
Zurück zum Zitat Coffin P. Overdose: a major cause of preventable death in Central and Eastern Europe in Central Asia: recommendations and overview of the situation in Latvia, Kyrgyzstan, Romania, Russia and Tajikistan. Vilnius, Lithuania: Eurasian Harm Reduction Network (EHRN)2008. Coffin P. Overdose: a major cause of preventable death in Central and Eastern Europe in Central Asia: recommendations and overview of the situation in Latvia, Kyrgyzstan, Romania, Russia and Tajikistan. Vilnius, Lithuania: Eurasian Harm Reduction Network (EHRN)2008.
65.
Zurück zum Zitat Grau LE, Green TC, Torban M, Blinnikova K, Krupitsky E, Ilyuk R, et al. Psychosocial and contextual correlates of opioid overdose risk among drug users in St. Petersburg, Russia. Harm Reduction J. 2009;6:17. doi:10.1186/1477-7517-6-17.CrossRef Grau LE, Green TC, Torban M, Blinnikova K, Krupitsky E, Ilyuk R, et al. Psychosocial and contextual correlates of opioid overdose risk among drug users in St. Petersburg, Russia. Harm Reduction J. 2009;6:17. doi:10.​1186/​1477-7517-6-17.CrossRef
67.•
Zurück zum Zitat Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013;70(12):1338–46. doi:10.1001/jamapsychiatry.2013.2295. As most trials of pharmacotherapies for stimulant use disorders are negative, even small trials that report positive results deserve particular attention.CrossRefPubMed Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013;70(12):1338–46. doi:10.​1001/​jamapsychiatry.​2013.​2295. As most trials of pharmacotherapies for stimulant use disorders are negative, even small trials that report positive results deserve particular attention.CrossRefPubMed
68.
Zurück zum Zitat Miles SW, Sheridan J, Russell B, Kydd R, Wheeler A, Walters C, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013;108(7):1279–86. doi:10.1111/add.12109.CrossRefPubMed Miles SW, Sheridan J, Russell B, Kydd R, Wheeler A, Walters C, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013;108(7):1279–86. doi:10.​1111/​add.​12109.CrossRefPubMed
69.
70.
Zurück zum Zitat Dursteler-MacFarland KM, Farronato NS, Strasser J, Boss J, Kuntze MF, Petitjean SA, et al. A randomized, controlled, pilot trial of methylphenidate and cognitive-behavioral group therapy for cocaine dependence in heroin prescription. J Clin Psychopharmacol. 2013;33(1):104–8. doi:10.1097/JCP.0b013e31827bfff4.CrossRefPubMed Dursteler-MacFarland KM, Farronato NS, Strasser J, Boss J, Kuntze MF, Petitjean SA, et al. A randomized, controlled, pilot trial of methylphenidate and cognitive-behavioral group therapy for cocaine dependence in heroin prescription. J Clin Psychopharmacol. 2013;33(1):104–8. doi:10.​1097/​JCP.​0b013e31827bfff4​.CrossRefPubMed
72.
Zurück zum Zitat Heinzerling KG, Gadzhyan J, van Oudheusden H, Rodriguez F, McCracken J, Shoptaw S. Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence. J Adolesc Health : Off Publ Soc Adolesc Med. 2013;52(4):502–5. doi:10.1016/j.jadohealth.2012.10.275.CrossRef Heinzerling KG, Gadzhyan J, van Oudheusden H, Rodriguez F, McCracken J, Shoptaw S. Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence. J Adolesc Health : Off Publ Soc Adolesc Med. 2013;52(4):502–5. doi:10.​1016/​j.​jadohealth.​2012.​10.​275.CrossRef
73.
Zurück zum Zitat Winhusen TM, Kropp F, Lindblad R, Douaihy A, Haynes L, Hodgkins C, et al. Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J Clin Psychiatry. 2014;75(7):757–64. doi:10.4088/JCP.13m08862.CrossRefPubMed Winhusen TM, Kropp F, Lindblad R, Douaihy A, Haynes L, Hodgkins C, et al. Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J Clin Psychiatry. 2014;75(7):757–64. doi:10.​4088/​JCP.​13m08862.CrossRefPubMed
74.
Zurück zum Zitat LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict / Am Acad Psychiatrists Alcohol and Addict. 2013;22(5):443–52. doi:10.1111/j.1521-0391.2013.12034.x. LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict / Am Acad Psychiatrists Alcohol and Addict. 2013;22(5):443–52. doi:10.​1111/​j.​1521-0391.​2013.​12034.​x.
76.
Zurück zum Zitat Somoza EC, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA, Galloway GP, et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry. 2013;70(6):630–7. doi:10.1001/jamapsychiatry.2013.872.CrossRefPubMed Somoza EC, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA, Galloway GP, et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry. 2013;70(6):630–7. doi:10.​1001/​jamapsychiatry.​2013.​872.CrossRefPubMed
77.
Zurück zum Zitat Verrico CD, Mahoney 3rd JJ, Thompson-Lake DG, Bennett RS, Newton TF, De La Garza 2nd R. Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2014;17(2):223–33. doi:10.1017/S146114571300134X.CrossRefPubMed Verrico CD, Mahoney 3rd JJ, Thompson-Lake DG, Bennett RS, Newton TF, De La Garza 2nd R. Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2014;17(2):223–33. doi:10.​1017/​S146114571300134​X.CrossRefPubMed
81.
Zurück zum Zitat Wang C, Vlahov D, Galai N, Cole SR, Bareta J, Pollini R, et al. The effect of HIV infection on overdose mortality. AIDS. 2005;19(9):935–42.CrossRefPubMed Wang C, Vlahov D, Galai N, Cole SR, Bareta J, Pollini R, et al. The effect of HIV infection on overdose mortality. AIDS. 2005;19(9):935–42.CrossRefPubMed
82.
Zurück zum Zitat Zaccarelli M, Gattari P, Rezza G, Conti S, Spizzichino L, Vlahov D, et al. Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS. 1994;8(3):345–50.CrossRefPubMed Zaccarelli M, Gattari P, Rezza G, Conti S, Spizzichino L, Vlahov D, et al. Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS. 1994;8(3):345–50.CrossRefPubMed
84.
Zurück zum Zitat Jenkins LM, Banta-Green CJ, Maynard C, Kingston S, Hanrahan M, Merrill JO, et al. Risk factors for nonfatal overdose at Seattle-area syringe exchanges. J Urban Health : Bull N Y Acad Med. 2011;88(1):118–28. doi:10.1007/s11524-010-9525-6.CrossRef Jenkins LM, Banta-Green CJ, Maynard C, Kingston S, Hanrahan M, Merrill JO, et al. Risk factors for nonfatal overdose at Seattle-area syringe exchanges. J Urban Health : Bull N Y Acad Med. 2011;88(1):118–28. doi:10.​1007/​s11524-010-9525-6.CrossRef
85.
Zurück zum Zitat Coffin PO, Coffin LM, Fitzpatrick T, Murphy S. Drug overdose, lay naloxone, and HIV risk behaviors among persons who inject drugs. XIX International AIDS Conference; July 23, 2012; Washington, DC2012. Abstract#MOPE218. Coffin PO, Coffin LM, Fitzpatrick T, Murphy S. Drug overdose, lay naloxone, and HIV risk behaviors among persons who inject drugs. XIX International AIDS Conference; July 23, 2012; Washington, DC2012. Abstract#MOPE218.
86.
Zurück zum Zitat Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001;322(7291):895–6.CrossRefPubMedCentralPubMed Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001;322(7291):895–6.CrossRefPubMedCentralPubMed
87.
Zurück zum Zitat Enteen L, Bauer J, McLean R, Wheeler E, Huriaux E, Kral AH, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health : Bull N Y Acad Med. 2010;87(6):931–41. doi:10.1007/s11524-010-9495-8.CrossRef Enteen L, Bauer J, McLean R, Wheeler E, Huriaux E, Kral AH, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health : Bull N Y Acad Med. 2010;87(6):931–41. doi:10.​1007/​s11524-010-9495-8.CrossRef
88.
Zurück zum Zitat Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health : Bull N Y Acad Med. 2011;88(6):1020–30. doi:10.1007/s11524-011-9600-7.CrossRef Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health : Bull N Y Acad Med. 2011;88(6):1020–30. doi:10.​1007/​s11524-011-9600-7.CrossRef
89.••
Zurück zum Zitat Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174. doi:10.1136/bmj.f174. This study of community-distribution of naloxone was the first to demonstrate a significant and dose-dependent association of naloxone distribution with reduced opioid overdose mortality.CrossRefPubMed Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174. doi:10.​1136/​bmj.​f174. This study of community-distribution of naloxone was the first to demonstrate a significant and dose-dependent association of naloxone distribution with reduced opioid overdose mortality.CrossRefPubMed
90.•
Zurück zum Zitat Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600. doi:10.7326/0003-4819-159-9-201311050-00005. Correctional populations remain at extremely high risk of HIV and HCV. These risks dovetail with an extremely high risk of overdose death, particularly in the 4 weeks after release from incarceration.CrossRefPubMed Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600. doi:10.​7326/​0003-4819-159-9-201311050-00005. Correctional populations remain at extremely high risk of HIV and HCV. These risks dovetail with an extremely high risk of overdose death, particularly in the 4 weeks after release from incarceration.CrossRefPubMed
95.
Zurück zum Zitat Williams AV, Marsden J, Strang J. Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes. Addiction. 2014;109(2):250–9. doi:10.1111/add.12360.CrossRefPubMed Williams AV, Marsden J, Strang J. Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes. Addiction. 2014;109(2):250–9. doi:10.​1111/​add.​12360.CrossRefPubMed
96.
Zurück zum Zitat Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158:1–9.CrossRefPubMed Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158:1–9.CrossRefPubMed
97.
Zurück zum Zitat Jozaghi E, Andresen MM. Should North America’s first and only supervised injection facility (InSite) be expanded in British Columbia, Canada? Harm Reduction J. 2013;10:1. doi:10.1186/1477-7517-10-1.CrossRef Jozaghi E, Andresen MM. Should North America’s first and only supervised injection facility (InSite) be expanded in British Columbia, Canada? Harm Reduction J. 2013;10:1. doi:10.​1186/​1477-7517-10-1.CrossRef
98.
Zurück zum Zitat Reddon H, Wood E, Tyndall M, Lai C, Hogg R, Montaner J, et al. Use of North America’s first medically supervised safer injecting facility among HIV-positive injection drug users. AIDS Educ Prev : Off Publ Int Soc AIDS Educ. 2011;23(5):412–22. doi:10.1521/aeap.2011.23.5.412.CrossRef Reddon H, Wood E, Tyndall M, Lai C, Hogg R, Montaner J, et al. Use of North America’s first medically supervised safer injecting facility among HIV-positive injection drug users. AIDS Educ Prev : Off Publ Int Soc AIDS Educ. 2011;23(5):412–22. doi:10.​1521/​aeap.​2011.​23.​5.​412.CrossRef
99.
Zurück zum Zitat Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235–48. doi:10.1093/ije/dyt243.CrossRefPubMed Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235–48. doi:10.​1093/​ije/​dyt243.CrossRefPubMed
100.
Zurück zum Zitat MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug policy. 2014;25(1):34–52. doi:10.1016/j.drugpo.2013.07.001.CrossRefPubMed MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug policy. 2014;25(1):34–52. doi:10.​1016/​j.​drugpo.​2013.​07.​001.CrossRefPubMed
Metadaten
Titel
Novel Interventions to Prevent HIV and HCV Among Persons Who Inject Drugs
verfasst von
Phillip O. Coffin
Christopher Rowe
Glenn-Milo Santos
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 1/2015
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-014-0248-2

Weitere Artikel der Ausgabe 1/2015

Current HIV/AIDS Reports 1/2015 Zur Ausgabe

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

T Memory Stem Cells and HIV: a Long-Term Relationship

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.